BOTHELL, Wash.--(BUSINESS WIRE)--MDRNA, Inc. (Nasdaq: MRNA) announced today that the National Institutes of Health (NIH) has awarded the Company over $350,000 for further development of the Company’s siRNA therapeutics program to prevent and treat influenza. These funds are part of a five-year grant totaling $1.9 million that the NIH awarded the Company in September 2006 to study the underlying scientific principles that enable RNAi to inhibit influenza.
